Nothing said here yet.
to join the conversation.
If you only skimmed the Medicare reimbursement headaches and net losses around AVITA Medical at the start of 2026, this outcome would be hard to guess. Holding AVITA Medical from the start of the year would have returned 347.0%, including dividends.
AVITA Medical’s updated valuation work now points to a fair value of $12.29, compared with the prior $11.06, which gives you a fresh reference point for where analysts see the stock’s central value today.
AVITA Medical to attend Lake Street and Morgan Stanley investor conferences in September
Avita Medical (RCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AVITA Medical is back in focus after fair value estimates in recent models shifted from US$9.00 to US$11.06, marking a sizeable uplift in the central price target.
Does Avita Medical Inc. (RCEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Avita Medical (NASDAQ:RCEL) presented results from its PermeaDerm-I study, a randomized controlled trial evaluating PermeaDerm as temporary wound coverage following excision and before split-thickness skin grafting, compared with cadaveric allograft.
Primary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product cost per percent total body surface area treated (p<0.001) 96% reduction in preparation time and comparable clinical outcomes to allograft including graft take,…
Avita Medical (NASDAQ:RCEL) reported second-quarter 2026 revenue of $21.7 million, up 13% sequentially from $19.3 million in the first quarter and 18% from $18.4 million a year earlier, as the wound-care company cited growth across its product portfolio and in U.S.
Avita Medical (NASDAQ:RCEL) expects continued sequential revenue growth and aims to reach cash flow breakeven in the fourth quarter of 2025, President and CEO Cary Vance said at the Canaccord 46th Annual Boston Growth Conference.
Revenue exceeded $21.7 million with guidance raised to $86M–$89M for full year.